You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePosaconazole
Accession NumberDB01263
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionPosaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • Sch 56592
  • SCH-56592
  • SCH56592
  • Schering 56592
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NoxafilSuspension40 mg/mLOralMerck Sharp & Dohme Corp.2006-09-15Not applicableUs
NoxafilTablet, delayed release100 mgOralMerck Sharp & Dohme Ltd2005-10-25Not applicableEu
NoxafilTablet, coated100 mg/1OralMerck Sharp & Dohme Corp.2013-11-25Not applicableUs
NoxafilTablet, delayed release100 mgOralMerck Sharp & Dohme Ltd2005-10-25Not applicableEu
NoxafilSolution18 mg/mLIntravenousMerck Sharp & Dohme Corp.2014-03-13Not applicableUs
NoxafilInjection, solution, concentrate300 mgIntravenousMerck Sharp & Dohme Ltd2005-10-25Not applicableEu
NoxafilSuspension40 mg/mlOralMerck Sharp & Dohme Ltd2005-10-25Not applicableEu
PosanolSuspension40 mgOralMerck Canada Inc2007-06-06Not applicableCanada
PosanolTablet, delayed release100 mgOralMerck Canada Inc2014-05-21Not applicableCanada
PosanolSolution18 mgIntravenousMerck Canada Inc2014-11-24Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Posaconazole SpSuspension40 mg/mlOralSchering Plough Europe2005-10-25Not applicableEu
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII6TK1G07BHZ
CAS number171228-49-2
WeightAverage: 700.7774
Monoisotopic: 700.329708282
Chemical FormulaC37H42F2N8O4
InChI KeyRAGOYPUPXAKGKH-XAKZXMRKSA-N
InChI
InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1
IUPAC Name
4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one
SMILES
[H][C@@](C)(O)[C@]([H])(CC)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@]2([H])CO[C@](CN3C=NC=N3)(C2)C2=C(F)C=C(F)C=C2)C=C1
Pharmacology
IndicationFor prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with prolonged neutropenia from chemotherapy. Also for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole. Posaconazole is used as an alternative treatment for invasive aspergillosis, Fusarium infections, and zygomycosis in patients who are intolerant of, or whose disease is refractory to, other antifungals.
Structured Indications
PharmacodynamicsPosaconazole is an antifungal agent structurally related to itraconazole. It is a drug derived from itraconzaole through the replacement of the chlorine substituents with flourine in the phenyl ring, as well as hydroxylation of the triazolone side chain. These modifications enhance the potency and spectrum of activity of the drug. Posaconazole can be either fungicial or fungistatic in action.
Mechanism of actionAs a triazole antifungal agent, posaconazole exerts its antifungal activity through blockage of the cytochrome P-450 dependent enzyme, sterol 14α-demethylase, in fungi by binding to the heme cofactor located on the enzyme. This leads to the inhibition of the synthesis of ergosterol, a key component of the fungal cell membrane, and accumulation of methylated sterol precursors. This results in inhibition of fungal cell growth and ultimately, cell death.
TargetKindPharmacological actionActionsOrganismUniProt ID
Lanosterol 14-alpha demethylaseProteinyes
antagonist
YeastP10613 details
Related Articles
AbsorptionPosaconazole is absorbed with a median Tmax of approximately 3 to 5 hours.
Volume of distribution
  • 1774 L
Protein bindingPosaconazole is highly protein bound (>98%), predominantly to albumin.
Metabolism

Posaconazole primarily circulates as the parent compound in plasma. Of the circulating metabolites, the majority are glucuronide conjugates formed via UDP glucuronidation (phase 2 enzymes). Posaconazole does not have any major circulating oxidative (CYP450 mediated) metabolites. The excreted metabolites in urine and feces account for ~17% of the administered radiolabeled dose.

Route of eliminationThe excreted metabolites in urine and feces account for ~17% of the administered radiolabeled dose.
Half lifePosaconazole is eliminated with a mean half-life (t½) of 35 hours (range 20 to 66 hours).
Clearance
  • 32 L/hr
  • 51 L/hr [Single-Dose Suspension Administration of 200 mg, fasted]
  • 21 L/hr [Single-Dose Suspension Administration of 200 mg, nonfat meal]
  • 14 L/hr [Single-Dose Suspension Administration of 200 mg, high fat meal]
  • 91 L/hr [Single-Dose Suspension Administration of 400 mg, fasted]
  • 43 L/hr [Single-Dose Suspension Administration of 400 mg with liquid nutritional supplement (14 g fat)]
ToxicityDuring the clinical trials, some patients received posaconazole up to 1600 mg/day with no adverse events noted that were different from the lower doses. In addition, accidental overdose was noted in one patient who took 1200 mg BID for 3 days. No related adverse events were noted by the investigator.
Affected organisms
  • Aspergillis, Candida and other fungi
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Posaconazole.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Posaconazole.Experimental, Illicit
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Posaconazole.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Posaconazole.Experimental, Illicit
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Posaconazole.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Posaconazole.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Posaconazole.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Posaconazole.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Posaconazole.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Posaconazole.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Posaconazole.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Posaconazole.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Posaconazole.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Posaconazole.Experimental
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Posaconazole.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Posaconazole.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Posaconazole.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Posaconazole.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Posaconazole.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Posaconazole.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Posaconazole.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Posaconazole.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Posaconazole.Approved, Illicit, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Posaconazole.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Posaconazole.Approved
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Posaconazole.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Posaconazole.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Posaconazole.Approved
AmiodaroneThe metabolism of Posaconazole can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Posaconazole.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Posaconazole.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Posaconazole.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Posaconazole.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Posaconazole is combined with Amrinone.Approved
AnagrelidePosaconazole may increase the QTc-prolonging activities of Anagrelide.Approved
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Posaconazole.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Posaconazole.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Posaconazole.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Posaconazole.Approved, Investigational
AprepitantThe serum concentration of Posaconazole can be increased when it is combined with Aprepitant.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Posaconazole.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Posaconazole.Approved, Investigational
Arsenic trioxidePosaconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Posaconazole.Approved
AsenapineThe serum concentration of Posaconazole can be decreased when it is combined with Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Posaconazole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Posaconazole.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Posaconazole.Approved
AtomoxetineThe metabolism of Posaconazole can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Posaconazole.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Posaconazole.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Posaconazole.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Posaconazole.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Azelnidipine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Posaconazole is combined with Azimilide.Investigational
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Posaconazole.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Posaconazole.Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Posaconazole.Approved
BeclomethasoneThe serum concentration of Beclomethasone can be increased when it is combined with Posaconazole.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Posaconazole.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Posaconazole.Approved
BenidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Benidipine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Posaconazole.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Posaconazole.Approved
BepridilThe risk or severity of adverse effects can be increased when Posaconazole is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Posaconazole.Approved, Vet Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Posaconazole.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Posaconazole.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Posaconazole.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Posaconazole.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Posaconazole.Approved
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Posaconazole.Approved, Investigational
BosentanThe serum concentration of Posaconazole can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Posaconazole.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Posaconazole.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Posaconazole.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Posaconazole.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Posaconazole.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Posaconazole.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Posaconazole.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Posaconazole.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Posaconazole.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Posaconazole.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Posaconazole.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Posaconazole.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Posaconazole.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Posaconazole.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Posaconazole.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Posaconazole.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Posaconazole.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Posaconazole.Approved
CaiThe risk or severity of adverse effects can be increased when Posaconazole is combined with Cai.Investigational
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Posaconazole.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Posaconazole.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Posaconazole.Approved
CarbamazepineThe metabolism of Posaconazole can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Posaconazole.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Posaconazole.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Posaconazole.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Posaconazole.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Posaconazole.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Posaconazole.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Posaconazole.Approved, Vet Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Posaconazole.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Posaconazole.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Posaconazole.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Posaconazole.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Posaconazole.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Posaconazole.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Posaconazole.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Posaconazole.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Posaconazole.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Posaconazole.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Posaconazole.Approved, Investigational
CilnidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Posaconazole.Approved
CimetidineThe serum concentration of Posaconazole can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Posaconazole.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Cinnarizine.Approved
CiprofloxacinPosaconazole may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Posaconazole.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Posaconazole.Approved
CitalopramThe metabolism of Citalopram can be decreased when combined with Posaconazole.Approved
ClarithromycinThe metabolism of Posaconazole can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Posaconazole can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Clevidipine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Posaconazole.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Posaconazole.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Posaconazole.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Posaconazole.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Posaconazole.Approved
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Posaconazole.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Posaconazole.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Posaconazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Posaconazole.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Posaconazole.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Posaconazole.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Posaconazole.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Posaconazole.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Posaconazole.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Posaconazole.Approved, Illicit
ClotrimazoleThe metabolism of Posaconazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Posaconazole.Approved
CobicistatThe metabolism of Posaconazole can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Posaconazole.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Posaconazole.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Posaconazole.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Posaconazole.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Posaconazole.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Posaconazole.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Posaconazole.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Posaconazole.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Posaconazole.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Posaconazole.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Posaconazole.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Posaconazole.Approved
DabrafenibThe serum concentration of Posaconazole can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Posaconazole.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Posaconazole.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Posaconazole.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Posaconazole.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Posaconazole.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Posaconazole.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Posaconazole.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Darodipine.Experimental
DarunavirThe metabolism of Darunavir can be decreased when combined with Posaconazole.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Posaconazole.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Posaconazole.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Posaconazole.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Posaconazole.Approved
DeferasiroxThe serum concentration of Posaconazole can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Posaconazole.Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Posaconazole.Approved
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Posaconazole.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Posaconazole.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Posaconazole.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Posaconazole.Approved
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Posaconazole.Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Posaconazole.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Posaconazole.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Posaconazole.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Posaconazole.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Posaconazole.Approved
DidanosineDidanosine can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Posaconazole.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Posaconazole.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Posaconazole.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Posaconazole.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Posaconazole.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Posaconazole.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Posaconazole.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Posaconazole.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Posaconazole.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Posaconazole.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Posaconazole.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Posaconazole.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Posaconazole.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Posaconazole.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Posaconazole.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Posaconazole.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Posaconazole.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Posaconazole.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Posaconazole.Approved
DotarizineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Dotarizine.Investigational
DoxepinThe serum concentration of Posaconazole can be decreased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Posaconazole.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Posaconazole.Approved, Investigational
DoxycyclineThe metabolism of Posaconazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Posaconazole.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Posaconazole.Approved
DroperidolPosaconazole may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Posaconazole.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Posaconazole.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Posaconazole.Approved
EfavirenzThe serum concentration of Posaconazole can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Posaconazole.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Posaconazole.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Posaconazole.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Posaconazole.Approved, Vet Approved
EnzalutamideThe serum concentration of Posaconazole can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Posaconazole is combined with Eperisone.Approved, Investigational
EpinastineThe serum concentration of Posaconazole can be decreased when it is combined with Epinastine.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Posaconazole.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Posaconazole.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Posaconazole.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Posaconazole.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Posaconazole.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Posaconazole.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Posaconazole.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Posaconazole.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Posaconazole.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Posaconazole.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Posaconazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Posaconazole can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Posaconazole.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Posaconazole.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Posaconazole.Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Posaconazole.Approved, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Posaconazole.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Posaconazole.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Posaconazole.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Posaconazole.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Posaconazole.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Posaconazole.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Posaconazole.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Posaconazole.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Posaconazole.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Posaconazole.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Posaconazole.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Posaconazole.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Posaconazole.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Posaconazole.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Posaconazole.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Posaconazole.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Posaconazole.Approved
FamotidineThe serum concentration of Posaconazole can be decreased when it is combined with Famotidine.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Posaconazole.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Posaconazole.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Fendiline.Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Posaconazole.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Posaconazole.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Posaconazole.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Posaconazole.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Posaconazole.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Posaconazole.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Posaconazole.Approved, Investigational
FlecainidePosaconazole may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Posaconazole.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Posaconazole.Investigational
FluconazoleThe metabolism of Posaconazole can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Posaconazole.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Posaconazole.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Posaconazole.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Flunarizine.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Posaconazole.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Posaconazole.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Posaconazole.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Posaconazole.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Posaconazole.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Posaconazole.Approved, Vet Approved
FlupentixolPosaconazole may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Posaconazole.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Posaconazole.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Posaconazole.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Posaconazole.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Posaconazole.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Posaconazole.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Posaconazole.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Posaconazole.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Posaconazole.Approved
FluvoxamineThe metabolism of Posaconazole can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Posaconazole.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be increased when Fosamprenavir is used in combination with Posaconazole.Approved
FosaprepitantThe serum concentration of Posaconazole can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Posaconazole can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Posaconazole.Approved, Investigational
Fusidic AcidThe serum concentration of Posaconazole can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Posaconazole is combined with Gabapentin.Approved, Investigational
Gadobenic acidPosaconazole may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Posaconazole.Approved
GallopamilThe risk or severity of adverse effects can be increased when Posaconazole is combined with Gallopamil.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Posaconazole.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Posaconazole.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Posaconazole.Approved
GemifloxacinPosaconazole may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlipizidePosaconazole may increase the hypoglycemic activities of Glipizide.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Posaconazole.Approved
GoserelinPosaconazole may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Posaconazole.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Posaconazole.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Posaconazole.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Posaconazole.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Posaconazole.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Posaconazole.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Posaconazole.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Posaconazole.Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Posaconazole.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Posaconazole.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Posaconazole.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Posaconazole.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Posaconazole.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Posaconazole.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Posaconazole.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Posaconazole.Approved
IbutilidePosaconazole may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Posaconazole can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Posaconazole resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Posaconazole.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Posaconazole.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Posaconazole.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Posaconazole.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Posaconazole.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Posaconazole.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Posaconazole.Approved
IndinavirThe metabolism of Posaconazole can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Posaconazole.Approved, Investigational
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Posaconazole.Approved
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Posaconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Posaconazole.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Posaconazole.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Posaconazole.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Posaconazole.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Posaconazole.Investigational
ItraconazoleThe metabolism of Posaconazole can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Posaconazole.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Posaconazole.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Posaconazole.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Posaconazole.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Posaconazole.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Posaconazole.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Posaconazole.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Posaconazole.Approved
KetoconazoleThe metabolism of Posaconazole can be decreased when combined with Ketoconazole.Approved, Investigational
LacidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Lacidipine.Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Posaconazole.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Posaconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Posaconazole can be decreased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Posaconazole.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Posaconazole.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Posaconazole.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Posaconazole.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Posaconazole.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Posaconazole.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Posaconazole.Approved, Investigational
LeuprolidePosaconazole may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Posaconazole.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Posaconazole.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Posaconazole.Approved
LevofloxacinPosaconazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Posaconazole.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Posaconazole.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Posaconazole.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Posaconazole.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Posaconazole.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Posaconazole.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Posaconazole.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Posaconazole.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Posaconazole.Approved
LopinavirThe metabolism of Lopinavir can be decreased when combined with Posaconazole.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Posaconazole.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Posaconazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Posaconazole.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Posaconazole.Approved, Investigational
LuliconazoleThe serum concentration of Posaconazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Posaconazole can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Posaconazole.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Posaconazole.Approved
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Posaconazole.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Posaconazole is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Posaconazole.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Posaconazole.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Posaconazole.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Posaconazole.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Posaconazole.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Posaconazole.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Posaconazole.Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Posaconazole.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Posaconazole.Approved, Vet Approved
MethadonePosaconazole may increase the QTc-prolonging activities of Methadone.Approved
MethanthelineThe serum concentration of Posaconazole can be decreased when it is combined with Methantheline.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Posaconazole.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Posaconazole.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Posaconazole.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Posaconazole.Approved, Vet Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Posaconazole.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Posaconazole.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Posaconazole.Approved
MetiamideThe serum concentration of Posaconazole can be decreased when it is combined with Metiamide.Experimental
MetoclopramideThe serum concentration of Posaconazole can be decreased when it is combined with Metoclopramide.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Posaconazole.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Posaconazole.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Posaconazole.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Posaconazole.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Posaconazole.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Posaconazole.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Posaconazole.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Posaconazole.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Posaconazole.Approved
MitotaneThe serum concentration of Posaconazole can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Posaconazole.Approved, Investigational
ModafinilThe metabolism of Modafinil can be decreased when combined with Posaconazole.Approved, Investigational
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Posaconazole.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Posaconazole.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Posaconazole.Approved, Investigational
MoxifloxacinPosaconazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Posaconazole.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Posaconazole.Approved
NafcillinThe serum concentration of Posaconazole can be decreased when it is combined with Nafcillin.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Posaconazole is combined with Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Posaconazole.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Posaconazole.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Posaconazole.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Posaconazole.Investigational
NefazodoneThe metabolism of Posaconazole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Posaconazole can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Posaconazole can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Posaconazole can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Posaconazole.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Posaconazole.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Posaconazole.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Posaconazole.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Niludipine.Experimental
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Posaconazole.Approved
NimesulideThe risk or severity of adverse effects can be increased when Posaconazole is combined with Nimesulide.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Posaconazole.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Posaconazole.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Posaconazole.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Posaconazole.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Posaconazole.Approved
NizatidineThe serum concentration of Posaconazole can be decreased when it is combined with Nizatidine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Posaconazole.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Posaconazole.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Posaconazole.Approved
OfloxacinPosaconazole may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Posaconazole can be decreased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Posaconazole.Approved
Oleoyl estroneThe serum concentration of Oleoyl estrone can be increased when it is combined with Posaconazole.Investigational
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Posaconazole.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Posaconazole.Approved
OmeprazoleThe serum concentration of Posaconazole can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Posaconazole.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Posaconazole.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Posaconazole.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Posaconazole.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Posaconazole.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Posaconazole.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Posaconazole is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Posaconazole.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Posaconazole.Approved
PaliperidonePosaconazole may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Posaconazole.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Posaconazole.Approved, Investigational
PantoprazoleThe serum concentration of Posaconazole can be decreased when it is combined with Pantoprazole.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Posaconazole.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Posaconazole.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Posaconazole.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Posaconazole.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Posaconazole.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Posaconazole.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Posaconazole.Approved
PentobarbitalThe metabolism of Posaconazole can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Posaconazole.Approved
PerflutrenPosaconazole may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Posaconazole.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Posaconazole.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Posaconazole.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Posaconazole.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Posaconazole.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Posaconazole.Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Posaconazole.Approved
PhenobarbitalThe metabolism of Posaconazole can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Posaconazole.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Posaconazole.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Posaconazole.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Posaconazole.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Posaconazole.Approved, Investigational
PimozidePosaconazole may increase the arrhythmogenic activities of Pimozide.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Posaconazole.Withdrawn
PinaveriumThe risk or severity of adverse effects can be increased when Posaconazole is combined with Pinaverium.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Posaconazole.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Posaconazole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Posaconazole.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Posaconazole.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Posaconazole.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Posaconazole.Approved
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Posaconazole.Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Posaconazole.Approved, Nutraceutical
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Posaconazole resulting in a loss in efficacy.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Posaconazole.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Posaconazole.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Posaconazole.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Posaconazole.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Posaconazole.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Posaconazole.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Posaconazole.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Posaconazole.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Posaconazole is combined with Pregabalin.Approved, Illicit, Investigational
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Posaconazole.Experimental
PrenylamineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Prenylamine.Withdrawn
PrimaquineThe metabolism of Primaquine can be decreased when combined with Posaconazole.Approved
PrimidoneThe metabolism of Posaconazole can be increased when combined with Primidone.Approved, Vet Approved
ProcainamidePosaconazole may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Posaconazole.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Posaconazole.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Posaconazole.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Posaconazole.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Posaconazole.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Posaconazole.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Posaconazole.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Posaconazole.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Posaconazole.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Posaconazole.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Posaconazole.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Posaconazole.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Posaconazole.Approved
RabeprazoleThe serum concentration of Posaconazole can be decreased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Posaconazole.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Posaconazole.Approved, Investigational
RanitidineThe serum concentration of Posaconazole can be decreased when it is combined with Ranitidine.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Posaconazole.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Posaconazole.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Posaconazole.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Posaconazole.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Posaconazole.Approved
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Posaconazole.Approved
RifabutinThe metabolism of Posaconazole can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Posaconazole can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Posaconazole can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Posaconazole.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Posaconazole.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Posaconazole.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Posaconazole.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Posaconazole.Approved
RisedronateThe risk or severity of adverse effects can be increased when Posaconazole is combined with Risedronate.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Posaconazole.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Posaconazole.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Posaconazole.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Posaconazole.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Posaconazole.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Posaconazole.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Posaconazole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Posaconazole.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Posaconazole.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Posaconazole.Approved
Roxatidine acetateThe serum concentration of Posaconazole can be decreased when it is combined with Roxatidine acetate.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Posaconazole.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Posaconazole.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Posaconazole.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Posaconazole.Approved
SaquinavirThe metabolism of Posaconazole can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Posaconazole.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Posaconazole.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Posaconazole.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Posaconazole.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Posaconazole.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Posaconazole.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Posaconazole.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Posaconazole.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Posaconazole.Approved
SiltuximabThe serum concentration of Posaconazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Posaconazole.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Posaconazole.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Posaconazole.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Posaconazole.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Posaconazole.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Posaconazole.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Posaconazole.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Posaconazole.Approved, Investigational
SotalolPosaconazole may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Posaconazole.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Posaconazole.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Posaconazole.Approved
St. John's WortThe serum concentration of Posaconazole can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Posaconazole can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Posaconazole.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Posaconazole.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Posaconazole.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Posaconazole.Approved
SulfisoxazolePosaconazole may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Posaconazole.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Posaconazole.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Posaconazole.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Posaconazole.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Posaconazole.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Posaconazole.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Posaconazole.Approved, Investigational
TAK-390MRThe serum concentration of Posaconazole can be decreased when it is combined with TAK-390MR.Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Posaconazole.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Posaconazole.Approved, Investigational
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Posaconazole.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Posaconazole.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Posaconazole.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Posaconazole.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Posaconazole.Approved
TelaprevirThe serum concentration of Posaconazole can be increased when it is combined with Telaprevir.Approved
TelavancinPosaconazole may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Posaconazole can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Posaconazole.Approved
TemsirolimusThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Posaconazole.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Posaconazole.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Posaconazole.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Posaconazole.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Posaconazole.Approved, Investigational
TetrabenazinePosaconazole may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Posaconazole.Approved, Vet Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Posaconazole.Approved
ThioridazinePosaconazole may increase the QTc-prolonging activities of Thioridazine.Approved
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Posaconazole.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Posaconazole.Approved
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Posaconazole resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Posaconazole.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Posaconazole.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Posaconazole.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Posaconazole.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Posaconazole.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Posaconazole.Approved
TocilizumabThe serum concentration of Posaconazole can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Posaconazole.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Posaconazole is combined with Tolfenamic Acid.Approved
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Posaconazole.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Posaconazole.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Posaconazole.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Posaconazole is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Posaconazole.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Posaconazole.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Posaconazole is combined with Tranilast.Approved, Investigational
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Posaconazole.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Posaconazole.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Posaconazole.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Posaconazole.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Posaconazole.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Posaconazole.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Posaconazole.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Posaconazole.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Posaconazole.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Posaconazole.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Posaconazole.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Posaconazole.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Posaconazole.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Posaconazole.Investigational, Withdrawn
VandetanibThe metabolism of Vandetanib can be decreased when combined with Posaconazole.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Posaconazole.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Posaconazole.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Posaconazole.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Posaconazole.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Posaconazole.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Posaconazole.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Posaconazole.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Posaconazole.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Posaconazole.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Posaconazole.Approved
VinblastineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Posaconazole.Approved, Investigational
VincristineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vindesine.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vinorelbine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Posaconazole.Approved
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Posaconazole.Approved
VoriconazoleThe metabolism of Posaconazole can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Posaconazole.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Posaconazole.Approved
XylometazolineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Xylometazoline.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Posaconazole.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Posaconazole.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Posaconazole.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Posaconazole.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Posaconazole is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Posaconazole.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Posaconazole.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Posaconazole.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Posaconazole.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Posaconazole.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Posaconazole.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Posaconazole.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Posaconazole.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Dominic De Souza, “PREPARATION OF POSACONAZOLE INTERMEDIATES.” U.S. Patent US20130203994, issued August 08, 2013.

US20130203994
General References
  1. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007 Jan 25;356(4):348-59. [PubMed:17251531 ]
  2. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 Jan 25;356(4):335-47. [PubMed:17251530 ]
  3. Bhattacharya M, Rajeshwari K, Dhingra B: Posaconazole. J Postgrad Med. 2010 Apr-Jun;56(2):163-7. doi: 10.4103/0022-3859.65281. [PubMed:20622401 ]
  4. Frampton JE, Scott LJ: Posaconazole : a review of its use in the prophylaxis of invasive fungal infections. Drugs. 2008;68(7):993-1016. [PubMed:18457464 ]
  5. Schiller DS, Fung HB: Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther. 2007 Sep;29(9):1862-86. [PubMed:18035188 ]
  6. Kwon DS, Mylonakis E: Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007 Jun;8(8):1167-78. [PubMed:17516880 ]
  7. Groll AH, Walsh TJ: Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther. 2005 Aug;3(4):467-87. [PubMed:16107193 ]
  8. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH: Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother. 2008 Oct;42(10):1429-38. doi: 10.1345/aph.1L005. Epub 2008 Aug 19. [PubMed:18713852 ]
  9. Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H: Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010 Jun;49(6):379-96. doi: 10.2165/11319340-000000000-00000. [PubMed:20481649 ]
External Links
ATC CodesJ02AC04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (183 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.5499
Caco-2 permeable+0.5332
P-glycoprotein substrateSubstrate0.7822
P-glycoprotein inhibitor IInhibitor0.7338
P-glycoprotein inhibitor IINon-inhibitor0.8895
Renal organic cation transporterNon-inhibitor0.7323
CYP450 2C9 substrateNon-substrate0.8131
CYP450 2D6 substrateNon-substrate0.8354
CYP450 3A4 substrateSubstrate0.6683
CYP450 1A2 substrateNon-inhibitor0.8484
CYP450 2C9 inhibitorInhibitor0.5281
CYP450 2D6 inhibitorNon-inhibitor0.8667
CYP450 2C19 inhibitorNon-inhibitor0.6409
CYP450 3A4 inhibitorNon-inhibitor0.5532
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5074
Ames testAMES toxic0.5235
CarcinogenicityNon-carcinogens0.7341
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8919 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5306
hERG inhibition (predictor II)Inhibitor0.6661
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solution, concentrateIntravenous300 mg
SolutionIntravenous18 mg/mL
SuspensionOral40 mg/ml
Tablet, coatedOral100 mg/1
SolutionIntravenous18 mg
SuspensionOral40 mg
Tablet, delayed releaseOral100 mg
Prices
Unit descriptionCostUnit
Noxafil 40 mg/ml suspension7.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2179396 No2001-04-172014-12-20Canada
CA2305803 No2009-12-222018-10-05Canada
US5661151 No1999-07-192019-07-19Us
US5703079 No1994-08-262014-08-26Us
US6958337 No1998-10-052018-10-05Us
US8263600 No2002-04-012022-04-01Us
US8410077 No2009-03-132029-03-13Us
US9023790 No2011-07-042031-07-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
logP5.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP4.71ALOGPS
logP5.41ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)14.83ChemAxon
pKa (Strongest Basic)3.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area111.79 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity200.71 m3·mol-1ChemAxon
Polarizability73.83 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Phenyl-1,3,4-triazole
  • Phenyl-1,2,4-triazole
  • Phenyltriazole
  • Substituted aniline
  • Dialkylarylamine
  • Phenol ether
  • Halobenzene
  • Fluorobenzene
  • Aniline
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Triazole
  • Oxolane
  • Azole
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Yeast
Pharmacological action
yes
Actions
antagonist
General Function:
Sterol 14-demethylase activity
Specific Function:
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
Gene Name:
ERG11
Uniprot ID:
P10613
Molecular Weight:
60674.965 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM: Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother. 2004 Jun;48(6):2124-31. [PubMed:15155210 ]
  4. Li X, Brown N, Chau AS, Lopez-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM: Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004 Jan;53(1):74-80. Epub 2003 Dec 4. [PubMed:14657086 ]
  5. Bhattacharya M, Rajeshwari K, Dhingra B: Posaconazole. J Postgrad Med. 2010 Apr-Jun;56(2):163-7. doi: 10.4103/0022-3859.65281. [PubMed:20622401 ]
  6. Schiller DS, Fung HB: Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther. 2007 Sep;29(9):1862-86. [PubMed:18035188 ]
  7. Kwon DS, Mylonakis E: Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007 Jun;8(8):1167-78. [PubMed:17516880 ]
  8. Groll AH, Walsh TJ: Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther. 2005 Aug;3(4):467-87. [PubMed:16107193 ]
  9. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  10. Warrilow AG, Melo N, Martel CM, Parker JE, Nes WD, Kelly SL, Kelly DE: Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. Antimicrob Agents Chemother. 2010 Oct;54(10):4225-34. doi: 10.1128/AAC.00316-10. Epub 2010 Jul 26. [PubMed:20660663 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Nagappan V, Deresinski S: Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007 Dec 15;45(12):1610-7. doi: 10.1086/523576. [PubMed:18190324 ]
  2. Kharuzhyk SA, Matskevich SA, Filjustin AE, Bogushevich EV, Ugolkova SA: Survey of computed tomography doses and establishment of national diagnostic reference levels in the Republic of Belarus. Radiat Prot Dosimetry. 2010 Apr-May;139(1-3):367-70. doi: 10.1093/rpd/ncq070. Epub 2010 Feb 24. [PubMed:20181649 ]
  3. Kwon DS, Mylonakis E: Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007 Jun;8(8):1167-78. [PubMed:17516880 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Nagappan V, Deresinski S: Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007 Dec 15;45(12):1610-7. doi: 10.1086/523576. [PubMed:18190324 ]
Comments
comments powered by Disqus
Drug created on May 16, 2007 11:41 / Updated on December 02, 2016 02:44